Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.77 |
| ▸ | GRPR | P30550 | 2/20 | 0.77 |
| ▸ | GLP1R | P43220 | 11/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.64 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | CALCR | P30988 | 3/20 | 0.61 |
| ▸ | CCKBR | P32239 | 4/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083828 | 0.94 | GLP1R (0.70) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL29366899 | 0.94 | GLP1R (0.70) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL31379433 | 0.89 | NMBR (0.70) | NMBRGRPRGLP1RGCGRCRHR1 | |
| SCHEMBL29367990 | 0.89 | CALCA (0.69) | GRPRGLP1RGCGR | |
| Demobesin 3 SCHEMBL31069836 | 0.87 | GRPR (1.00) | NMBRGRPRGLP1RGCGRCRHR1 | |
| SCHEMBL23273229 | 0.87 | NMBR (0.69) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL25665363 | 0.84 | CTSL (0.69) | NMBRGRPRGLP1RGCGRCCKBR | |
| SCHEMBL30932062 | 0.84 | GLP1R (0.74) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL29599666 | 0.84 | GLP1R (0.70) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL30537032 | 0.84 | CALCR (0.78) | NMBRGRPRGLP1RGCGRCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3827015-B1 | GIP/GLP1 CO-AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12453758-B2 | Method of using a GIP/GLP1 co-agonist for diabetes | ELI LILLY AND COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250241995-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | ELI LILLY AND COMPANY | 2025-07-31 | — | — | US | disclosed |
| EP-4587462-A1 | GIP AND GLP-1 DUAL AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12295987-B2 | Method of using a GIP/GLP1 co-agonist for diabetes | ELI LILLY AND COMPANY (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4549454-A2 | GIP/GLP1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250122259-A9 | GIP/GLP1 CO-AGONIST COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12252524-B2 | GIP/GLP1 co-agonist compounds | ELI LILLY AND COMPANY (US) | 2025-03-18 | — | — | US | disclosed |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119504975-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4093757-A1 | GIP/GLP1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115298207-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11433119-B2 | Methods of treating inflammatory skin disorders | NEPSONE EHF (IS) | 2022-09-06 | — | — | US | disclosed |
| WO-2022177744-A1 | GIP/GLP1 DUAL AGONIST THERAPEUTIC METHODS | ELI LILLY AND COMPANY (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4007593-A1 | GIPR-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| US-20220127315-A1 | GIPR-AGONIST COMPOUNDS | ELI LILLY AND COMPANY | 2022-04-28 | — | — | US | disclosed |
| US-11266718-B2 | Methods of treating inflammatory skin disorders | NEPSONE EHF (IS) | 2022-03-08 | — | — | US | disclosed |
| US-20220048967-A1 | GIP/GLP1 CO-AGONIST COMPOUNDS | LILLY CO ELI (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453758-B2 | Method of using a GIP/GLP1 co-agonist for diabetes | GLP1R, GIPR, GCGR | NMBR 781/4885GRPR 4/4885GLP1R 1/4885 |
| US-12252524-B2 | GIP/GLP1 co-agonist compounds | GLP1R, GIPR, GCGR | NMBR 1296/4885GRPR 5/4885GLP1R 1/4885 |
| US-20250241995-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | GLP1R, GIPR, GCGR | NMBR 781/4885GRPR 4/4885GLP1R 1/4885 |
| US-20220048967-A1 | GIP/GLP1 CO-AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | NMBR 1296/4885GRPR 5/4885GLP1R 1/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | NMBR 1901/4885GRPR 3116/4885GLP1R 3683/4885 |
| US-12295987-B2 | Method of using a GIP/GLP1 co-agonist for diabetes | GLP1R, GIPR, GCGR | NMBR 821/4885GRPR 5/4885GLP1R 1/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | NMBR 356/4885GRPR 9/4885GLP1R 2/4885 |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | NMBR 1901/4885GRPR 3116/4885GLP1R 3683/4885 |
| US-20250122259-A9 | GIP/GLP1 CO-AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | NMBR 1296/4885GRPR 5/4885GLP1R 1/4885 |
| US-20220127315-A1 | GIPR-AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | NMBR 529/4885GRPR 5/4885GLP1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.